Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment Sanna-Kaisa Herukka,

Slides:

Advertisements

Similar presentations

COST CM1103 Training School Structure-based drug design for diagnosis and treatment of neurological diseases Istanbul, 9-13 Sept 2013 Mirjana Babić, mag.biol.mol.

Advertisements

Structural and Functional Neuroimaging in the Diagnosis of Dementia John M. Ringman, M.D. Assistant Professor UCLA Department of Neurology.

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

DECIDE: "Scientific and Clinical Perspectives“: Claudio Babiloni (UNIFG) and Giovanni Frisoni (IRCCS Brescia)

Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment Lies Clerx, Ineke A. van.

DIAGNOSTIC ACCURACY AND CONFIDENCE IN THE CLINICAL DETECTION OF COGNITIVE IMPAIRMENT IN EARLY-STAGE PARKINSON’S DISEASE Kathryn A. Wyman-Chick, Phillip.

Volume 3, Issue 4, Pages (November 2017)

José L Molinuevo, Craig Ritchie, Miia Kivipelto

Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer’s disease study Wesley.

Arg-ADNI Patients’ Flowchart Patients Invited to ADNI Nº= 73

Different pathways to Alzheimer’s disease

Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease Azadeh Karami, Helga Eyjolfsdottir, Swetha.

Cerebrospinal fluid biomarkers for Alzheimer's disease are associated with neuropathology in cortical brain biopsy Toni Seppälä, Ossi Nerg, Anne Koivisto,

Correlations between amyloid and metabolic pet imaging in cognitively normal adults with a family history of late-onset Alzheimer's disease Megan Cummings,

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

Use of Amyloid PET Scan in Early Diagnosis of Alzheimer’s Disease in a Secondary Care Memory Clinic Niki Schoonenboom, MD PhD1, Mohammed Akarriou, MD2;

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

INCREASED CSF LEVELS OF BIOMARKERS FOR NEURODEGENERATION IN FTLD-GRN MUTATION CARRIERS Joery Goossens, Sara Van Mossevelde, Tobi Van den Bossche, Anne.

SERUM NEUROFILAMENT LIGHT PROTEIN PREDICTS CLINICAL OUTCOME IN TRAUMATIC BRAIN INJURY Pashtun Shahim, Magnus Gren, Victor Liman, Ulf Andreasson, Niklas.

Volume 3, Issue 2, Pages (June 2017)

Dement Geriatr Cogn Disord Extra 2014;4: DOI: /

Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints Argonde C. van Harten, Pieter Jelle Visser,

Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design Arno de Wilde, Ingrid S. van Maurik, Marleen Kunneman, Femke Bouwman, Marissa.

Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia Anja Hviid Simonsen, Sanna-Kaisa Herukka, Niels Andreasen, Ines Baldeiras,

Detecting functional decline from normal aging to dementia: Development and validation of a short version of the Amsterdam IADL Questionnaire Roos J.

Alzheimer's disease biomarker-based clusters predict amyloid accumulation and cognitive decline in a preclinical cohort: Findings from the wisconsin registry.

Application of Resource Utilization in Dementia (RUD) instrument in a global setting Anders Wimo, Anders Gustavsson, Linus Jönsson, Bengt Winblad, Ming-Ann.

Alzheimer’s disease core biomarkers and prediction of dementia in MCI: The effect of age at onset Anna Caroli, Samantha Galluzzi, Clarissa Ferrari, Annapaola.

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

DETECTING COGNITIVE DISORDERS USING THE MUISTIKKO WEB-BASED COGNITIVE TEST BATTERY: VALIDATION IN THREE COHORTS Teemu Paajanen, Shadi Mahdiani, Marie.

Image Challenge Q: A 70-year-old woman presented to the neurology clinic with a 2-year history of gait disturbance, cognitive impairment, and urinary incontinence.

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

Volume 2, Issue 1, Pages (January 2016)

Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin Eva Carro, Fernando Bartolomé, Félix Bermejo-Pareja,

Imaging AD Progression Amyloid Imaging Agents.

Early Dementia Distinguishing AD From MCI

Reisa Sperling, Elizabeth Mormino, Keith Johnson Neuron

Blood-Based Biomarkers in the QC Program?

Probing the Biology of Alzheimer's Disease in Mice

José L Molinuevo, Craig Ritchie, Miia Kivipelto

Chris Hyde Exeter Test Group.

Tharick A. Pascoal, Sulantha Mathotaarachchi, Monica Shin, Andrea L

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups.

Prevalence and incidence of clinically diagnosed Alzheimer's disease dementia from 1994 to 2012 in a population study Kumar B. Rajan, Jennifer Weuve,

Application of Resource Utilization in Dementia (RUD) instrument in a global setting Anders Wimo, Anders Gustavsson, Linus Jönsson, Bengt Winblad, Ming-Ann.

A nonhuman primate model of early Alzheimer's disease pathologic change: Implications for disease pathogenesis Caitlin S. Latimer, Carol A. Shively,

Clifford R. Jack, Heather J. Wiste, Stephen D. Weigand, Terry M

Prevalence and incidence of clinically diagnosed Alzheimer's disease dementia from 1994 to 2012 in a population study Kumar B. Rajan, Jennifer Weuve,

Longitudinal uncoupling of cerebral perfusion, glucose metabolism, and tau deposition in Alzheimer's disease Antoine Leuzy, Elena Rodriguez-Vieitez,

Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective Matthew Baumgart, Heather M. Snyder,

Early cost-utility analysis of general and cerebrospinal fluid-specific Alzheimer's disease biomarkers for hypothetical disease-modifying treatment decision.

A 22-single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid Aβ42 Kristel Sleegers,

The incremental diagnostic value of 18F-florbetapir imaging in naturalistic patients with cognitive impairment: The India-FBP study Marina Boccardi,

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

Linus Jönsson, Pei-Jung Lin, Ara S. Khachaturian

Added value of 11C-PiB-PET imaging in the diagnosis of Alzheimer's disease Kristian Frederiksen, Anne-Mette Hejl, Ian Law, Steen Hasselbalch, Gunhild.

Idiopathic Intracranial Hypertension

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

Cerebral hypoperfusion is not associated with an increase in amyloid β pathology in middle-aged or elderly people Oskar Hansson, Sebastian Palmqvist,

DIFFERENCES IN ANALYTICAL SELECTIVITY OF β-AMYLOID (1-42) IMMUNOASSAYS EXPLAIN DISCORDANT RESULTS IN STUDY COMPARISONS Hugo Marcel Vanderstichele, Emeric.

Intersite variability of CSF Alzheimer’s disease biomarkers in clinical setting Julien Dumurgier, Olivier Vercruysse, Claire Paquet, Stéphanie Bombois,

Different pathways to Alzheimer’s disease

Fig. 1. AD biomarker levels in the cerebrospinal fluid of iNPH, AD, and CN subjects. Box plots of Aβ42 (A), Aβ40 (B), Aβ42/Aβ40 ratio (C), t-tau (D),

Fig. 2. Correlation between Aβ42 and Aβ40 levels in iNPH, AD, and CN subjects. The scatter plot shows the correlation between Aβ42 and Aβ40 levels. Representative.

Suzanne E. Schindler, Julia D. Gray, Brian A

A nonhuman primate model of early Alzheimer's disease pathologic change: Implications for disease pathogenesis Caitlin S. Latimer, Carol A. Shively,

BRAIN AMYLOIDOSIS AND COGNITIVE DECLINE IN MCI: 12-MONTH FOLLOW-UP

Detecting and Diagnosing Alzheimer’s Disease

CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER.

Presentation transcript:

Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment Sanna-Kaisa Herukka, Anja Hviid Simonsen, Niels Andreasen, Ines Baldeiras, Maria Bjerke, Kaj Blennow, Sebastiaan Engelborghs, Giovanni B. Frisoni, Tomasz Gabryelewicz, Samantha Galluzzi, Ron Handels, Milica G. Kramberger, Agnieszka Kulczyńska, Jose Luis Molinuevo, Barbara Mroczko, Agneta Nordberg, Catarina Resende Oliveira, Markus Otto, Juha O. Rinne, Uroš Rot, Esen Saka, Hilkka Soininen, Hanne Struyfs, Silvia Suardi, Pieter Jelle Visser, Bengt Winblad, Henrik Zetterberg, Gunhild Waldemar Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 13, Issue 3, Pages 285-295 (March 2017) DOI: 10.1016/j.jalz.2016.09.009 Copyright © 2016 The Authors Terms and Conditions

Fig. 1 Decision tree on the recommended use of the cerebrospinal fluid (CSF) biomarkers in diagnostic workup on patients with clinical diagnosis of mild cognitive impairment. *Diagnosis based on medical history, clinical and basic neuropsychological examination, and basic neuroimaging. MCI, mild cognitive impairment; MRI, magnetic resonance imaging; MTA, medial temporal lobe atrophy; AD, Alzheimer's disease; FDG, fluorodeoxyglucose; PET, positron-emission tomography; Aβ, amyloid-β; P-tau, phosphorylated tau. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2017 13, 285-295DOI: (10.1016/j.jalz.2016.09.009) Copyright © 2016 The Authors Terms and Conditions